Read our latest updates & insights

On 22 January 2026, Daiichi Sankyo announced that Enhertu® (trastuzumab deruxtecan) has been approved by China’s National Medical Products Administration (NMPA) as the first and only HER2-directed antibody-drug conjugate for the second line treatment of adults with HER2 pos...

The Ontario government has reported that it is fast-tracking funding for a number of cancer drugs including the combination of BMS’ Opdivo® (nivolumab) and Yervoy® (ipilimumab) for treatment of both colorectal and liver cancers.

A number of nivolumab biosimilars are ...

Zydus has wasted no time in announcing the launch of its nivolumab biosimilar, Tishtha™, on 22 January 2026, following the High Court of Delhi’s 12 January 2026 reversal on appeal of a preliminary injunction granted to BMS in relation to the biosimilar.

Zydus’ nivolu...

On 22 January 2026, Zhitong Finance reported that AstraZeneca’s Imfinzi® (durvalumab) was approved by China’s National Medical Products Administration (NMPA) for use, in combination with carboplatin and paclitaxel, as a first-line treatment for adult patients with mismatch ...

In its Q3/FY26 earnings call on 21 January 2026, Dr Reddy’s announced that its abatacept biosimilar, referencing BMS’ Orencia®, is expected to be approved in the US at the end of 2026 in IV form and in early 2028 in a subcutaneous formulation, with launches soon after those...

Head of Litigation (New Zealand), Paul Johns, talks with expert IP mediator Sheana Wheeldon about mediation of intellectual property disputes in New Zealand.  The introduction of a new fast-track Commercial List for IP litigation and recent reforms to general court procedur...

On 19 January 2026, Hikma announced the US launch of Enoby™ and Xtrenbo™ (denosumab-gbde), biosimilars to Amgen’s Prolia® and Xgeva® respectively.

Enoby™ and Xtrenbo™ were approved by the FDA in September 2025.  The biosimilars were developed and are manufactured by ...